Clinical trial · Observational
Real World Study of Linperlisib for Lymphoma Treatment
Real World Study of Linperlisib for Lymphoma Treatment: Multicenter, Non-interventional and Observational Real-world Study
NCT05863871CI-TRIAL-00066528MA-LYM-RWS-001not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a multicenter, non-interventional and observational real-world study to evaluate the efficacy and safety of linperlisib in patients with lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Focus on the Lymphoma Including B/T-cell Lymphoma | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Linperlisib | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- all enrolled patients
- description
- All patient who signed the consent form for participation to the study
- interventionNames
- Drug: Linperlisib
Primary outcomes (1)
- measure
- Rate of adverse events (AEs)/ serious adverse events (SAEs)
- timeFrame
- up to 4 weeks after the last dose
- description
- Rate of adverse events (AEs)/ serious adverse events (SAEs) in patients with lymphoma receiving linperlisib therapy
Secondary outcomes (4)
- measure
- Complete response rate
- timeFrame
- 6 months
- description
- Percentage of participants with complete response was determined on the basis of investigator assessments according to 2014 Lugano criteria.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥18 years 2. Clinical diagnosis of lymphoma patients 3. Patients signed informed consent, volunteered to join the study, and had the willingness and ability to cooperate with the data collection in this study; 4. The researchers' assessment can use Linperlisib treatment Exclusion Criteria: 1. The nature of the study could not be understood or informed consent was not obtained 2. Other ineligible conditions were assessed by the investigator
References
Publications (0)
Data not yet available
No reference posted for this study.